Cardiovascular disease

Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, March 26, 2024
Cardiovascular disease, Conference, Interest

SANTA CLARA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from Monday, April 8 to Thursday, April 11, 2024.

Key Points: 
  • SANTA CLARA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from Monday, April 8 to Thursday, April 11, 2024.
  • Shockwave’s management is scheduled for a live fireside chat on Tuesday, April 9, 2024, at 8:45 a.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at: https://ir.shockwavemedical.com .

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Retrieved on: 
Tuesday, April 9, 2024
Cardiology, Biotechnology, Technology, Health, General Health, Pharmaceutical, Health Technology, Other Technology, Medical Devices, Artificial Intelligence, Genetics, Diagnosis, Exponential, Cardio, Genomics, Cardiovascular disease, Growth, Entrepreneurship, Partnership, Risk, Patient, Artificial intelligence, Splenic infarction, Death, CHD, Medicine, Concierge medicine, Epigenomics, Moyamoya disease, USD, Medical device

As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.

Key Points: 
  • As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.
  • Concierge practices such as Exponential Health are leading the way in adopting epigenetic cardiovascular solutions.
  • "We are thrilled to partner with Dr. Baer and Exponential Health," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.
  • Integrating Cardio Diagnostics' advanced tests into Exponential Health's offerings is a proactive step toward mitigating this global health challenge.

United States Cardiovascular Devices Market, Size, Share, Forecast 2024-2030 Featuring Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Cardinal Health, Medtronic, GE, J&J, & Siemens - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Health, Medical Devices, Cardiology, Hospital, Cardiac catheterization, Disease, American Heart Association, Stent, Cardiovascular disease, Coronary artery disease, Prevalence, Biotechnology, CVD, ECG, Incidence, Diabetes, Electrocardiography, Public, Research, Mortality, Insight, Death, Risk, Arrhythmia, Diagnosis, Heart failure, CAD, Medical device

Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.

Key Points: 
  • Consequently, producers are investing in innovation and developing new cardiovascular devices to satisfy growing healthcare wishes, expanding the increase in the United States cardiovascular devices market.
  • Technology is pivotal in employing growth in the United States cardiovascular devices market.
  • Numerous market players actively enforce strategic tasks, propelling an increase in the United States cardiovascular devices market.
  • In the United States cardiovascular devices market, diagnostics and monitoring devices have a significant presence
    The United States cardiovascular device market is broken up by device type into Diagnostics and Monitoring Devices and Therapeutic and Surgical Devices.

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Retrieved on: 
Monday, April 8, 2024
Research, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, JAMA, American Medical Association, Cardiovascular disease, Serum, Patient, Journal, RNA, MD, Therapy, Moyamoya disease, Safety, Small RNA, APOLLO, ASCVD, Pharmaceutical industry

“Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.

Key Points: 
  • “Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.
  • Results from the single ascending dose portion of the trial in healthy participants were previously published in the April 2022 issue of JAMA, linked here .
  • Secondary outcomes included the serum levels of zerlasiran and effects on Lp(a) serum concentrations.
  • Zerlasiran is currently being evaluated in the ALPACAR-360 phase 2 study in subjects with baseline Lp(a) levels at or over 125 nmol/L at high risk of ASCVD events.

LIB Therapeutics Announces Positive Results from LIBerate-HR Study: A 52-Week, Placebo-Controlled Registration-Enabling Trial of Lerodalcibep at Late-Breaking Session at American College of Cardiology 2024

Retrieved on: 
Monday, April 8, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Week, Temperature, Cardiovascular disease, PCSK9, CVD, ADAS, FH, Patient, Travel, Female, Refrigeration, OLE, MBBS, Marketing, European Medicines Agency, American College, Therapy, Liberation, ITT, Safety, Food, ACC, Apolipoprotein B, Apolipoprotein, Pharmaceutical industry

Patients were randomized 2:1 to a single 300 mg (1.2 mL subcutaneous) once-monthly dose of Lerodalcibep or placebo for 52 weeks.

Key Points: 
  • Patients were randomized 2:1 to a single 300 mg (1.2 mL subcutaneous) once-monthly dose of Lerodalcibep or placebo for 52 weeks.
  • Of 478 participants in the base LIBerate-HeFH trial, 421 (88%) continued into the OLE trial: 281 patients on Lerodalcibep and 140 on placebo.
  • All participants received open-label Lerodalcibep 300 mg in a subcutaneous 1.2 mL once-monthly dose starting immediately upon completion of the base trial.
  • After 48 weeks of OLE treatment, mean % LDL-C reductions with Lerodalcibep from baseline in the base trial was 48.5% (ITT population).

CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024

Retrieved on: 
Sunday, April 7, 2024
Technology, Medical Devices, Surgery, Health Technology, Cardiology, Software, Other Health, General Health, Health, Artificial Intelligence, Diagnosis, TTE, Machine learning, Cardiovascular disease, Coronary artery disease, Pulmonary hypertension, Patient, Heart, Heart failure, American College, Data collection, FDA, CAD

The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.

Key Points: 
  • The CorVista System is the world’s first non-invasive point-of-care solution for evaluating the presence of coronary artery disease and pulmonary hypertension.
  • Timely identification of left ventricular dysfunction plays a pivotal role in effective heart failure management, however, measuring elevated LVEDP currently relies on invasive left heart catheterization.
  • Sc.D., Executive Vice President and Chief Scientific Officer, CorVista Health.
  • “We believe the CorVista System can uniquely and effectively address these important unmet needs for people living with cardiovascular disease, especially in rural and underserved populations.”

Genomics plc and MassMutual's program enables more policyowners to understand health risks through innovative genetic testing

Retrieved on: 
Tuesday, April 9, 2024
Health, MassMutual, Cardiovascular disease, Face, Prostate cancer, Learning, Disease, Partnership, Atrial fibrillation, Diabetes, Genetics, Risk, Patient, Ageing, DNA, Breast, Insurance, Risk assessment, Privacy, Nursing

OXFORD, England and SPRINGFIELD, Mass., April 9, 2024 /PRNewswire/ -- Genomics plc (Genomics), a healthcare company transforming health through the power of genomics, and MassMutual, a leading mutual life insurance company in the United States, today announced the next phase of their innovative partnership enabling more eligible MassMutual policyowners to gain knowledge about their health in order to make informed, proactive decisions that may help them lead longer, healthier lives. The program offers a genetic risk assessment service to these individuals, providing insight into their personalized risk for eight major diseases. The expansion follows a successful research collaboration in which more than 70% of policyowners who elected to use the risk assessment service reported intent to take preventative actions based on their risk scores, including plans to see their doctor or seek further screening.

Key Points: 
  • The program offers a genetic risk assessment service to these individuals, providing insight into their personalized risk for eight major diseases.
  • Genomics' at-home test studies millions of small variations in DNA, generating polygenic risk scores, that can inform the likelihood of certain conditions.
  • During the initial Genomics and MassMutual research collaboration, 1 in 5 policyowners learned that they are at a higher risk for preventable diseases.
  • MassMutual only receives high-level, anonymized data from Genomics that allows the company to better understand aggregate policyowners' health and behaviors and interest in these types of offerings.

New Clinical Study Reveals Consuming 12 Eggland's Best Eggs Weekly Shows No Negative Effects on Cholesterol Levels; Study Also Suggests Possible Benefits for Some Consumers

Retrieved on: 
Monday, April 8, 2024
Research, Health, LDL, Cardiovascular disease, Vitamin, Nutrient, Cardiology, Diabetes, Risk, Patient, Senior, American College, Clinical trial, HDL, Cholesterol, Egg as food, Duke, Vitamin B12, Pharmaceutical industry

CEDAR KNOLLS, N.J., April 8, 2024 /PRNewswire/ -- Americans are increasingly aware of the impact of cholesterol on heart health and well-being, but for decades, there have been conflicting headlines about which foods can have positive or negative effects. Eggs, in particular, have often received negative press related to cholesterol. However, a new study presented at the American College of Cardiology's Annual Scientific Session that was led by researchers at Duke and sponsored by Eggland's Best, offers promising new evidence on fortified eggs.

Key Points: 
  • The clinical trial studied 140 participants from a broadly generalized population who had a high risk of heart disease.
  • Researchers randomized participants into two groups, asking half to eat two or fewer eggs per week for four months.
  • Ultimately, the study found that over 4 months, eating Eggland's Best eggs resulted in no adverse effects on lipid profiles and markers of cardiovascular risk for these patients.
  • The consumption of Eggland's Best eggs may also increase Vitamin B12 levels, also helping to support a healthier lifestyle.

Filippo Berio announces exclusive partnership with Alzheimer's Drug Discovery Foundation, supporting critical research and brain health

Retrieved on: 
Monday, April 8, 2024
Olive, Fillit, American Museum, Olive oil, Health, Diet, Brain, Cardiovascular disease, Cauchy stress tensor, Natural history, Polyphenol, Antioxidant, Entrepreneurship, Entomology, Partnership, Risk, Inflammation, Ageing, Research, Traffic barrier, MD, Marketing, Cancer, Filippo Berio, Dementia, Drug discovery

LYNDHURST, N.J., April 8, 2024 /PRNewswire/ -- Filippo Berio, one of the nation's top-selling and longstanding olive oil brands, has established an exclusive partnership with the Alzheimer's Drug Discovery Foundation to raise awareness for Alzheimer's disease and contribute crucial funds to support groundbreaking research aimed at finding a cure for Alzheimer's and related dementias. The collaboration is a natural fit, given the growing body of research that indicates properties in olive oil may not only play a pivotal role in cardiovascular health but also provide important benefits to brain health. The partnership aims to increase overall awareness of lifestyle changes, including a healthy diet, that may positively affect brain health, which can help consumers to make healthier, informed choices.

Key Points: 
  • The collaboration is a natural fit, given the growing body of research that indicates properties in olive oil may not only play a pivotal role in cardiovascular health but also provide important benefits to brain health.
  • The partnership aims to increase overall awareness of lifestyle changes, including a healthy diet, that may positively affect brain health, which can help consumers to make healthier, informed choices.
  • Studies indicate that consuming olive oil may have protective effects on the brain and reduce the risk of Alzheimer's."
  • This will be the second consecutive year Filippo Berio is supporting one of the ADDF's signature fundraising events.

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on: 
Monday, April 8, 2024
Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points: 
  • The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
  • Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
  • Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
  • The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.